Results 161 to 170 of about 17,989 (193)
Some of the next articles are maybe not open access.
Novel Therapies for ANCA-associated Vasculitis
Current Rheumatology Reports, 2021The purpose of this review is to discuss the most recent evidence on the treatment innovations and future prospective in the management of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAVs).In AAV, a growing body of research is available on novel treatment options for remission induction and to clarify some uncertainties ...
Monti S. +5 more
openaire +5 more sources
Giornale italiano di nefrologia : organo ufficiale della Societa italiana di nefrologia, 2002
ANCA-associated vasculitis. The term "antineutrophil cytoplasm antibody (ANCA)- associated vasculitis" (AASV) ihighers generally used to include primary vasculitis syndromes in which circulating ANCA against proteinase 3 (PR3) and myeloperoxidase (MPO) are commonly found.
SINICO, RENATO ALBERTO +3 more
openaire +2 more sources
ANCA-associated vasculitis. The term "antineutrophil cytoplasm antibody (ANCA)- associated vasculitis" (AASV) ihighers generally used to include primary vasculitis syndromes in which circulating ANCA against proteinase 3 (PR3) and myeloperoxidase (MPO) are commonly found.
SINICO, RENATO ALBERTO +3 more
openaire +2 more sources
Classification of ANCA-Associated Vasculitis
Current Rheumatology Reports, 2013Classification of the ANCA-associated vasculitides remains controversial. Existing systems, developed by the American College of Rheumatology (ACR) in 1990, the Chapel Hill Consensus Conference (CHCC) in 1994 and updated in 2012, and the European Medicines Agency algorithm, all have deficiencies, especially when applied to unselected patients.
Irfan, Khan, Richard A, Watts
openaire +2 more sources
The History of ANCA-associated Vasculitis
Rheumatic Disease Clinics of North America, 2010An essential early step toward understanding vasculitis was recognition in 1948 of the differences between the small artery disease of polyarteritis, essentially sparing the glomerulus and lungs, and disease of glomerular vessels and small veins, often involving the lungs.
openaire +2 more sources
Pathology of ANCA-associated vasculitis
Clinical and Experimental Nephrology, 2012According to the recent 2012 Chapel Hill Consensus Conference, ANCA-associated vasculitis is classified in the group of small vessel vasculitis. Pauci-immune necrotizing crescentic glomerulonephritis is the morphological hallmark of ANCA-associated vasculitis.
Ferrario, F, Vanzati, A, PAGNI, FABIO
openaire +2 more sources
Treatment of ANCA-Associated Vasculitis
New England Journal of Medicine, 2003Vasculitis is defined by inflammation of the blood-vessel wall and forms the pathological foundation of a diverse group of individual disease entities. Among the primary systemic vasculitic diseases, Wegener's granulomatosis and microscopic polyangiitis share several common features, including pulmonary capillaritis, pauci-immune focal crescentic ...
openaire +2 more sources
Vasculitis for the internist: focus on ANCA-associated vasculitis
Internal and Emergency Medicine, 2017Vasculitides comprise several diseases affecting vessels of different sizes, mainly arteries, but also capillaries and veins. Antineutrophil cytoplasm antibody-associated vasculitides (AAVs) belong to the systemic necrotizing small-vessel vasculitis group that comprises granulomatosis with polyangiitis, microscopic polyangiitis and eosinophilic ...
Benjamin, Chaigne, Loïc, Guillevin
openaire +2 more sources
Autoantibodies in ANCA-associated Vasculitis
Rheumatic Disease Clinics of North America, 2010Antineutrophil cytoplasmic autoantibody (ANCA)-associated vasculitides are systemic or more limited conditions characterized by necrotizing destruction of small and medium-sized vessels (eg, capillaries, venules, and arterioles). ANCAs are the most predominant autoantibodies in patients affected by vasculitis, but other autoantibodies may also occur ...
openaire +2 more sources
Respiratory Failure in ANCA-Associated Vasculitis
Chest, 1996To assess the prevalence, clinical manifestations, and course of respiratory failure in all patients who tested positive for antineutrophil cytoplasmic autoantibodies (ANCA) in our clinics in the period between January 1985 and January 1993.Case-series analysis.Three teaching hospitals in the Netherlands.Two hundred twenty consecutive patients ...
J C, ter Maaten +4 more
openaire +3 more sources